Company: BLRX
Filing Date: 2025-01-07
Form Type: 424B5
Source: 0001178913-25-000045
Chunk: 18

Company: BioLineRx Ltd.
Filing Date: 2025-01-07
Form: 424B5
Chunk 18
---
 other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms including “anticipates,” “believes,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” and “would,” and similar expressions intended to identify forward-looking statements. Factors that could cause or contribute to these differences include those listed below as well as those discussed in the section entitled “Risk Factors” contained in our most recent Annual Report on Form 20-F. You should not put undue reliance on any forward-looking statements. Our actual results could differ materially from those discussed in the forward-looking statements. Unless we are required to do so under U.S. federal securities laws or other applicable laws, we do not intend to update or revise any forward-looking statements. Readers are encouraged to consult our filings made on Form 6-K, which are periodically filed with or furnished to the SEC. Factors that could cause our actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to:

| • | the clinical development, commercialization and market acceptance of our therapeutic candidates, including the degree and pace of market uptake of APHEXDA for the mobilization of hematopoietic stem cells for autologous transplantation in 
 multiple myeloma patients;                                                                                                                                                                                                                    |

| • | the initiation, timing, progress and results of our preclinical studies, clinical trials and other therapeutic candidate development efforts; |

| • | the clinical development, commercialization and market acceptance of our therapeutic candidates, including the degree and pace of market uptake of APHEXDA for the mobilization of hematopoietic stem cells for autologous transplantation in 
 multiple myeloma patients;                                                                                                                                                                                                                    |

| • | the initiation, timing, progress and results of our preclinical studies, clinical trials and other therapeutic candidate development efforts; |

| • | our ability to advance our therapeutic candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; |

| • | whether the clinical trial results for APHEXDA will be predictive of real-world results; |

| • | our receipt of regulatory approvals for our therapeutic candidates and the timing of other regulatory filings and approvals; |

| • | whether access to APHEXDA is achieved in a commercially viable manner